SGEN vs. BIIB, NBIX, GILD, AMGN, MRNA, ARGX, BNTX, TECH, ALC, and IQV
Should you be buying Seagen stock or one of its competitors? The main competitors of Seagen include Biogen (BIIB), Neurocrine Biosciences (NBIX), Gilead Sciences (GILD), Amgen (AMGN), Moderna (MRNA), argenx (ARGX), BioNTech (BNTX), Bio-Techne (TECH), Alcon (ALC), and IQVIA (IQV). These companies are all part of the "medical" sector.
Seagen vs.
Biogen (NASDAQ:BIIB) and Seagen (NASDAQ:SGEN) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, community ranking, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.
In the previous week, Seagen had 6 more articles in the media than Biogen. MarketBeat recorded 20 mentions for Seagen and 14 mentions for Biogen. Seagen's average media sentiment score of 1.08 beat Biogen's score of 0.65 indicating that Biogen is being referred to more favorably in the media.
Biogen has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.
Biogen currently has a consensus price target of $325.36, indicating a potential upside of 27.58%. Seagen has a consensus price target of $190.47, indicating a potential downside of 11.62%. Given Seagen's stronger consensus rating and higher possible upside, research analysts clearly believe Biogen is more favorable than Seagen.
Biogen has a net margin of 26.72% compared to Biogen's net margin of -33.54%. Seagen's return on equity of 17.33% beat Biogen's return on equity.
86.0% of Biogen shares are held by institutional investors. Comparatively, 84.3% of Seagen shares are held by institutional investors. 0.6% of Biogen shares are held by company insiders. Comparatively, 25.9% of Seagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Biogen has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Comparatively, Seagen has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500.
Biogen received 985 more outperform votes than Seagen when rated by MarketBeat users. Likewise, 72.00% of users gave Biogen an outperform vote while only 63.70% of users gave Seagen an outperform vote.
Summary
Biogen beats Seagen on 14 of the 18 factors compared between the two stocks.
Get Seagen News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGEN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools